Savage Philip, Millrain Maggie, Dimakou Sofia, Stebbing Justin, Dyson Julian
Department of Medical Oncology, Charing Cross Hospital, London, UK.
Tumour Biol. 2007;28(2):70-6. doi: 10.1159/000099152. Epub 2007 Jan 29.
The expansion of cytotoxic CD8+ T lymphocytes (CTLs) which recognize peptide epitopes of tumour or viral origin has been a major aim of immunotherapy research for the past decade. Alongside the established dendritic cell-based methods, more recent approaches using recombinant MHC class I peptide complexes have been developed.
In this study we have explored the potential of a simplified system using soluble streptavidin-linked MHC class I tetramers to expand antigen-specific CTLs in vitro and in vivo.
In vitro tetramer-mediated expansion of CD8+ CTLs recognizing HLA-2/Melan-A and HLA-A2/Gag complexes was demonstrated with PBMCs from healthy donors or HIV+ donors, respectively. With 3 weekly rounds of tetramer stimulation, cell numbers expanded 100-fold from 0.05 to 5.0%. The lytic function of HLA-A2/Melan-A-expanded cells was demonstrated in 51Cr release assays by specific killing of T2 cells pulsed with Melan-A, but not other peptides. Similarly, murine CD8+ T cells specific for the HY epitope H2-Db/Uty could be expanded in vitro over a wide range of tetramer concentrations (0.008-1.0 microg/ml), with a single exposure producing substantial T cell expansion from 0.11 to 36%. Intraperitoneal administration of H2-Db/Uty tetramers to primed C57BL/6 mice produced over 5-fold expansion of Db/Uty-specific CTL in vivo.
The results in this paper demonstrate that simple, multimeric MHC complexes may be of value in expanding CTLs in vitro for adoptive immunotherapy and also potentially in vivo. Further studies will be necessary to clarify the optimum protocols and schedules of administration for T cell expansion using recombinant MHC multimers.
在过去十年中,识别肿瘤或病毒来源肽表位的细胞毒性CD8 + T淋巴细胞(CTL)的扩增一直是免疫治疗研究的主要目标。除了已确立的基于树突状细胞的方法外,还开发了使用重组MHC I类肽复合物的最新方法。
在本研究中,我们探索了一种简化系统的潜力,该系统使用可溶性链霉亲和素连接的MHC I类四聚体在体外和体内扩增抗原特异性CTL。
体外实验分别用来自健康供体或HIV +供体的外周血单核细胞(PBMC)证明了识别HLA - 2 / Melan - A和HLA - A2 / Gag复合物的CD8 + CTL的四聚体介导的扩增。经过3周每周一轮的四聚体刺激,细胞数量从0.05%扩增到5.0%,扩增了100倍。在51Cr释放试验中,通过特异性杀伤用Melan - A脉冲的T2细胞,而不是其他肽,证明了HLA - A2 / Melan - A扩增细胞的裂解功能。同样,对HY表位H2 - Db / Uty特异的小鼠CD8 + T细胞可以在体外多种四聚体浓度(0.008 - 1.0微克/毫升)范围内扩增,单次暴露可使T细胞大量扩增,从0.11%增至36%。向致敏的C57BL / 6小鼠腹腔内注射H2 - Db / Uty四聚体在体内使Db / Uty特异性CTL扩增超过5倍。
本文结果表明,简单的多聚体MHC复合物在体外扩增CTL用于过继免疫治疗以及潜在的体内应用中可能具有价值。需要进一步研究以阐明使用重组MHC多聚体进行T细胞扩增的最佳方案和给药时间表。